Extensive stage small cell carcinoma of the bronchus - A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide

Graham M. Mead, Joyce Thompson, John W. Sweetenham, Roger B. Buchanan, J. Michael A. Whitehouse, Christopher J. Williams

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Fifty-four patients whose disease had been staged as extensive small cell carcinoma of the bronchus were randomised to receive either CAV1 (cyclophosphamide 600 mg m-2 i.v., adriamycin 50 mg m-2 i.v., given on day 1, and etoposide 500 mg m-2 p.o. given on day 3) or CAV5 (cyclophosphamide and adriamycin given as for CAV1, etoposide 500 mg m-2 given in divided dose over days 3-7) on a 21-day schedule. The two regimens proved comparable (CR+PR 55% vs 56%), and the survival curves were virtually superimposable (median survival: CAV1, 8 months; CAV5, 9 months). Only five patients are still alive. The toxicity of the two treatments was similar. The scheduling of etoposide over 1 or 5 days seemed clinically unimportant in this study, perhaps because of concurrent use of other effective chemotherapy drugs.

Original languageEnglish (US)
Pages (from-to)172-174
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume19
Issue number2
DOIs
StatePublished - Apr 1 1987
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Extensive stage small cell carcinoma of the bronchus - A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide'. Together they form a unique fingerprint.

  • Cite this